Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer

Kaira,Kyoichi; Oriuchi,Noboru; Imai,Hisao; Shimizu,Kimihiro; Yanagitani,Noriko; Sunaga,Noriaki; Hisada,Takeshi; Kawashima,Osamu; Kamide,Yosuke; Ishizuka,Tamotsu; Kanai,Yoshikatsu; Nakajima,Takashi; Mori,Masatomo

doi:10.3892/etm.2010.117

Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer

Authors:
- Kyoichi Kaira
- Noboru Oriuchi
- Hisao Imai
- Kimihiro Shimizu
- Noriko Yanagitani
- Noriaki Sunaga
- Takeshi Hisada
- Osamu Kawashima
- Yosuke Kamide
- Tamotsu Ishizuka
- Yoshikatsu Kanai
- Takashi Nakajima
- Masatomo Mori
View Affiliations

Affiliations: Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan, Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan, Deparment of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan, Department of Surgery, National Nishi-Gunma Hospital, Gunma, Japan, Department of Respiratory Medicine, National Nishi-Gunma Hospital, Gunma, Japan, Division of Bio-system Pharmacology, Department of Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Tumor Pathology, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan
Published online on: July 20, 2010 https://doi.org/10.3892/etm.2010.117
Pages: 799-808

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to evaluate the prognostic value of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in patients with stage III non-small cell lung cancer (NSCLC). A total of 188 consecutive patients with pathologic stage III NSCLC were retrospectively reviewed. The expression of LAT1, CD98, Ki-67 labeling index, vascular endothelial growth factor (VEGF) as well as microvessel density (MVD) were evaluated immunohistochemically and correlated with the prognosis of patients after complete resection of the tumor. Positive expression of LAT1 and CD98 was noted in 58% (109/188) and 50% (94/188) of the cases, respectively (p=0.1473). A positive rate of LAT1 expression was significantly higher in squamous cell carcinoma (SQC) (90%, 48/53) and large-cell carcinoma (LCC) (100%, 12/12) than in adenocarcinoma (AC) (40%, 49/123). Moreover, a positive rate of LAT1 with CD98 expression was also significantly higher in SQC (74%, 39/53) and LCC (75%, 9/12) than AC (34%, 42/123). LAT1 expression was significantly higher in patients with mediastinal lymph node metastases than in patients without, and was significantly correlated with CD98, Ki-67 labeling index, VEGF and MVD. The 5-year survival rates of LAT1-positive and -negative patients and CD98-positive and -negative patients were 27.9 and 40.6% (p=0.0033), respectively, and 24.1 and 43.6% (p=0.0004), respectively. Multivariate analysis confirmed that positive expression of LAT1 and CD98 was an independent factor predicting a poor prognosis. In conclusion, the overexpression of LAT1 and CD98 is a pathological factor for predicting the prognosis of patients with surgically resectable stage III NSCLC.

View Figures

View References

1.	Shottenfeld D: Epidemiology of Lung Cancer. Lippincott-Raven; Philadelphia, PA: 1996
2.	Graziano SL: Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 17(Suppl 1): 37–58. 1997. View Article : Google Scholar
3.	Mountain CF: Revision in the International System for Staging Lung Cancer. Chest. 11:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
4.	Andre F, Grunenwald D, Pignon JP, et al: Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 18:2981–2989. 2000.PubMed/NCBI
5.	Leong SS, Rocha Lima CM, Sherman CA and Green MR: The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest. 115:242–248. 1999. View Article : Google Scholar : PubMed/NCBI
6.	Jassem J, Skokowski J, Dziadziuszko R, et al: Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg. 119:1141–1146. 2000. View Article : Google Scholar
7.	Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 15:2996–3018. 1997.PubMed/NCBI
8.	Christensen HN: Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 70:43–77. 1990.PubMed/NCBI
9.	McGivan JD and Pastor-Anglada M: Regulatory and molecular aspects of mammalian amino acid transport. Biochem J. 299:321–334. 1994.PubMed/NCBI
10.	Oxender DL and Christensen HN: Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature. 197:765–767. 1963. View Article : Google Scholar : PubMed/NCBI
11.	Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998. View Article : Google Scholar : PubMed/NCBI
12.	Yanagida O, Kanai Y, Chairoungdua A, et al: Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 1514:291–302. 2001. View Article : Google Scholar : PubMed/NCBI
13.	Ohkame H, Masuda H, Ishii Y and Kanai Y: Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol. 78:265–272. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Kaira K, Oriuchi N, Imai H, et al: Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer. Br J Cancer. 98:742–748. 2008.
15.	Kaira K, Oriuchi N, Imai H, et al: Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract. 204:553–561. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Nakanishi K, Ogata S, Matsuo H, et al: Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch. 451:681–690. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Nawashiro H, Otani N, Shinomiya N, et al: L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 119:484–492. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Chairoungdua A, Segawa H, Kim JY, et al: Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem. 274:28845–28848. 1999. View Article : Google Scholar : PubMed/NCBI
19.	Matsuo H, Tsukada S, Nakata T, et al: Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport. 11:3507–3511. 2000. View Article : Google Scholar : PubMed/NCBI
20.	Buck AC, Schirrmeister HH, Guhlmann CA, et al: Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med. 42:721–725. 2001.PubMed/NCBI
21.	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
22.	Mineo TC, Ambrogi V, Baldi A, et al: Prognostic impact of VEGF, CD31, CD34 and CD105 expression and tumor vessel invasion after radical surgery for IB–IIA non-small cell lung cancer. J Clin Pathol. 57:591–597. 2004.PubMed/NCBI
23.	Fucks BC, Finger RE, Onan MC and Bode BP: ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol. 293:55–63. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Kaira K, Oriuchi N, Imai H, et al: L-type amino acid transporter 1 (LAT1) and CD98 expression in the primary site and the metastatic site of human neoplasms. Cancer Sci. 99:2380–2386. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Rintoul RC, Buttery RC, Mackinnon AC, et al: Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell. 13:2841–2852. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Esteban F, Ruiz-Cabello F, Concha A, Perez Ayala M, Delgado M and Garrido F: Relationship of 4F2 antigen with local growth and metastatic potential of squamous cell carcinoma of the larynx. Cancer. 66:1493–1498. 1990. View Article : Google Scholar : PubMed/NCBI
27.	Kaira K, Oriuchi N, Otani Y, et al: Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathological study. Clin Cancer Res. 13:6369–6378. 2007.
28.	Martin B, Paesmans M, Mascaux C, et al: Ki-67 expression and patient survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 91:2018–2025. 2005. View Article : Google Scholar : PubMed/NCBI
29.	Han H, Silverman JF, Santucci TS, et al: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 8:72–79. 2001. View Article : Google Scholar : PubMed/NCBI
30.	Oriuchi N, Higuchi T, Ishikita T, et al: Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci. 97:1291–1297. 2006. View Article : Google Scholar : PubMed/NCBI
31.	Kaira K, Oriuchi N, Otani Y, et al: Diagnostic usefulness of fluorine-18-α-methyltyrosine positron emission tomography in combination with ¹⁸F-fluorodeoxyglucose in sarcoidosis patients. Chest. 131:1019–1027. 2007.
32.	Inoue T, Koyama K, Oriuchi N, et al: Detection of malignant tumors: whole-body PET with fluorine-18-α-methyl tyrosine versus FDG-preliminary study. Radiology. 220:54–62. 2001.
33.	Tomiyoshi K, Amed K, Muhammad S, et al: Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: L-F-alpha-methyl tyrosine using separation and purification system. Nucl Med Commun. 18:169–175. 1997. View Article : Google Scholar
34.	Kim DK, Kanai Y, Choi HW, et al: Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta. 1565:112–122. 2002. View Article : Google Scholar : PubMed/NCBI
35.	Kaira K, Oriuchi N, Shimizu K, et al: Evaluation of thoracic tumors with ¹⁸F-FMT and ¹⁸F-FDG PET-CT: a clinicopathological study. Int J Cancer. 124:1152–1160. 2009.PubMed/NCBI
36.	Kim CS, Cho SH, Chun HS, et al: BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull. 31:1096–1100. 2008. View Article : Google Scholar : PubMed/NCBI
37.	Berghmans T, Meert AP, Martin B, Ninane V and Sculier JP: Prognostic role of epidermal growth factor receptor in stage III non-small cell lung cancer. Eur Respir J. 25:329–335. 2005. View Article : Google Scholar : PubMed/NCBI
38.	Berghmans T, Mascaux C, Martin B, Ninane V and Sculier JP: Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Lung Cancer. 52:219–224. 2006. View Article : Google Scholar : PubMed/NCBI